EMA Authorised: Tagrisso (osimertinib mesilate) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency authorised Tagrisso (osimertinib mesilate) for use in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: AstraZeneca AB. Decision date: 03/12/2025. Accelerated assessment